Etoposide sensitizes CT26 colorectal adenocarcinoma to radiation therapy in BALB/c mice

doi:10.3748/wjg.v11.i31.4895

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 31

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2651)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series.

Item

Count

PDF

267

HTML

2207

Figures (1-4)

177

Sum=2651

Aug 21, 2005 (publication date) through Nov 7, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Reports

World J Gastroenterol. Aug 21, 2005; 11(31): 4895-4898
Published online Aug 21, 2005. doi: 10.3748/wjg.v11.i31.4895

Full Size Figure Download Figure

Figure 3 Plasma ALT and creatinine levels after killing of BALB/c mice implanted with CT26 colorectal adenocarcinoma cells. From left to right are: control group, etoposide group, RT group, and combination therapy group.

Citation: Liu CY, Liao HF, Wang TE, Lin SC, Shih SC, Chang WH, Yang YC, Lin CC, Chen YJ. Etoposide sensitizes CT26 colorectal adenocarcinoma to radiation therapy in BALB/c mice. World J Gastroenterol 2005; 11(31): 4895-4898
URL: https://www.wjgnet.com/1007-9327/full/v11/i31/4895.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i31.4895